Antagonizing the α4β1 integrin, but not α4β7, inhibits leukocytic infiltration of the central nervous system in rhesus monkey experimental autoimmune encephalomyelitis.
about
Promising biological therapies for ulcerative colitis: A review of the literatureInflammatory pathways of importance for management of inflammatory bowel diseaseAnti-α4 antibody treatment blocks virus traffic to the brain and gut early, and stabilizes CNS injury late in infectionEffectiveness and safety of vedolizumab for treatment of Crohn's disease: a systematic review and meta-analysisMeta-analysis of the effectiveness and safety of vedolizumab for ulcerative colitisDesigning biologic selectivity for inflammatory bowel disease--role of vedolizumabLoading into nanoparticles improves quercetin's efficacy in preventing neuroinflammation induced by oxysterolsNeuroimmunotherapies Targeting T Cells: From Pathophysiology to Therapeutic Applications.Tissue transglutaminase in marmoset experimental multiple sclerosis: discrepancy between white and grey matter.Expression of IL-1β in rhesus EAE and MS lesions is mainly induced in the CNS itself.Induction of experimental autoimmune encephalomyelitis with recombinant human myelin oligodendrocyte glycoprotein in incomplete Freund's adjuvant in three non-human primate species.Vedolizumab: toward a personalized therapy paradigm for people with ulcerative colitis.Challenges and approaches for the development of safer immunomodulatory biologics.Vedolizumab for the treatment of ulcerative colitis.Targeting integrins and adhesion molecules to combat inflammatory bowel disease.Biological therapy for ulcerative colitis: an update.Vedolizumab: a review of its use in adult patients with moderately to severely active ulcerative colitis or Crohn's disease.Evolving strategies to reduce colectomy rates in primary sclerosing cholangitis-inflammatory bowel disease: clinical remission of corticosteroid refractory colitis post-liver transplant with vedolizumab.Targeting vascular and leukocyte communication in angiogenesis, inflammation and fibrosis.Synthetic Retinoid AM80 Ameliorates Lung and Arthritic Autoimmune Responses by Inhibiting T Follicular Helper and Th17 Cell Responses.Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease in Patients Naïve to or Who Have Failed Tumor Necrosis Factor Antagonist Therapy.Migration of encephalitogenic CD8 T cells into the central nervous system is dependent on the α4β1-integrin.A Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Vedolizumab.Vedolizumab for ulcerative colitis and Crohn's disease: results and implications of GEMINI studies.Comment on 'anti-adhesion therapies and the rule of 3 for rare events'.Effect of PF-00547659 on Central Nervous System Immune Surveillance and Circulating β7+ T Cells in Crohn's Disease: Report of the TOSCA Study.Current and novel anti-inflammatory drug targets for inhibition of cytokines and leucocyte recruitment in rheumatic diseases.ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an Infectious Diseases perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphat
P2860
Q26776139-EA867D6E-69EF-4A51-8715-77F5E18F3E89Q27005445-0E4DD882-629F-4107-A8D1-A19234C4045BQ27322602-45500FAB-B4AB-4F81-960B-02D70F3D9E3AQ28067760-8963CD1B-3EC9-443A-9CB0-855EC571F4ACQ28080984-FCF359FF-5EBE-4DFB-B6FD-179A080F33E2Q28083872-801D23D8-200A-4980-9380-C34F19FB666EQ28538558-92A6BBF8-6093-4A7E-9367-926700303ADCQ30699740-694F2D18-50C4-42B9-8248-A79AF7885F9AQ35193921-7F98F561-086C-4FD5-B480-9F8CBCB1679DQ36976299-36AB8137-2E6D-4B61-81BC-CE72FABCAE84Q37467994-A6E03007-6310-471E-B36C-D75DC10E7228Q37691599-3D3A3D8C-3C89-46D6-B2B2-99B817103B3AQ38093772-02378902-7A00-4947-899B-63A5EBB5268CQ38209809-89281FEE-32DB-42FC-8E5B-36EC1A6E4384Q38248635-39A55C56-50F8-4B00-96C9-E85F80E6C901Q38259532-B0D1FE21-E3A8-4303-A9EF-C2B0CABC64FAQ38287244-4DB2A7AD-3569-467D-A55D-9F874D9FBA04Q38608954-5B3CA594-E6D4-4627-B607-6A287745E8B5Q38650120-F0A54D40-53D4-4A41-BE1E-F12C3330DB27Q38994454-286645A4-82B5-45BC-81B6-EC17A55407F7Q39120032-0BBF1F2E-F2DB-48CD-A73E-0ACDA3757422Q39219113-49D01627-D6BF-4511-9F53-7F09D1D17A09Q39317326-CA39A8D6-346A-46EF-9FCB-A46BABFEF65FQ45124604-84B87DEB-16CE-47B6-A3D4-A580ADA5DF89Q46265800-D1B08E9B-9E71-4758-80F5-EE81FBD7C26CQ46861949-E94DE3CD-7F9D-46C7-A7BF-95D3D833B25CQ48129259-CB90A469-00B3-4FC5-A8E9-6F7A6E0B5953Q50086043-F8C6433E-7E18-4376-ABD9-289395DF0CC1
P2860
Antagonizing the α4β1 integrin, but not α4β7, inhibits leukocytic infiltration of the central nervous system in rhesus monkey experimental autoimmune encephalomyelitis.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Antagonizing the α4β1 integrin ...... autoimmune encephalomyelitis.
@en
Antagonizing the α4β1 integrin ...... autoimmune encephalomyelitis.
@nl
type
label
Antagonizing the α4β1 integrin ...... autoimmune encephalomyelitis.
@en
Antagonizing the α4β1 integrin ...... autoimmune encephalomyelitis.
@nl
prefLabel
Antagonizing the α4β1 integrin ...... autoimmune encephalomyelitis.
@en
Antagonizing the α4β1 integrin ...... autoimmune encephalomyelitis.
@nl
P2093
P356
P1476
Antagonizing the α4β1 integrin ...... autoimmune encephalomyelitis.
@en
P2093
Bert A 't Hart
Dave M Lopes Estêvão
Eric R Fedyk
Krista G Haanstra
Li-Li Yang
Sam O Hofman
Vilmos Csizmadia
P304
P356
10.4049/JIMMUNOL.1202490
P407
P50
P577
2013-01-30T00:00:00Z